Digital Training Platform, Upskill TB, Strengthens Capacity to Deliver New DR-TB Treatments JAKARTA (October 9, 2025)—TB Alliance, in collaboration with
The six-month, all-oral BPaL/M regimens for the treatment of drug-resistant TB (DR-TB) are already changing the trajectory of DR-TB care
A new analysis, published in IJTLD Open, from South Africa and the Philippines further confirms that six-month, all-oral BPaL/M regimens
NEW YORK (September 12, 2025)—Lupin Limited, a leading pharmaceutical company headquartered in India, has been granted prequalification by the World
Capacity building program in the Philippines empowers Bangladesh NTP managers to scale up BPaL and BPaL/M regimens MAKATI CITY, PHILIPPINES—PeerLINC
A new economic evaluation has added powerful evidence to the already strong case for wide, global adoption of BPaL and
The World Health Organization’s (WHO) new guidance on Country Preparedness for the Introduction and Appropriate Use of Antibiotics highlighted TB
Collaboration Aims to Strengthen Health Systems and Accelerate Development of Next-Generation Treatments JAKARTA (July 30, 2025)—The Ministry of Health of
Regional meeting in Peru convened by PeerLINC, a global peer-to-peer initiative, brings together 20 countries to accelerate collaboration and scale-up
TB Alliance’s third licensed manufacturer makes pretomanid available through the Global Drug Facility, further improving affordability and access TB Alliance
